News brief­ing: ADC gets a speedy FDA re­view for their DL­B­CL ther­a­py; Qi­a­gen teams with the world's new fa­vorite biotech

The transat­lantic biotech ADC Ther­a­peu­tics is get­ting a speedy re­view for its an­ti-body drug con­ju­gate lon­cas­tux­imab tesirine (Lon­ca), de­vel­oped for re­lapsed or re­frac­to­ry dif­fuse large …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER